论文部分内容阅读
目的:探讨重组人类促红细胞生成素(EPO)防治早产儿贫血的疗效。方法:将35例胎龄<35周、出生体重1 200～2 500 g的早产儿随机分为两组。治疗组18例,出生后第1周即应用EPO 200 IU/kg,隔日1次,每周3次,共5周;对照组17例未予EPO治疗。两组早产儿生后第10天开始口服铁剂及维生素E,必要时输血。结果:治疗8周后治疗组患儿静脉血红细胞(RBC)、血红蛋白(Hb)、网织红细胞(Ret)均高于对照组(P<0.01)。结论:早期应用EPO可防治早产儿贫血,减少早产儿输血次数。
Objective: To investigate the effect of recombinant human erythropoietin (EPO) on prevention and treatment of anemia in premature infants. Methods: 35 cases of gestational age <35 weeks, birth weight 1200 ~ 2500 g of premature children were randomly divided into two groups. The treatment group, 18 cases, the first week after birth that is, EPO 200 IU / kg, every other day, 3 times a week for 5 weeks; control group, 17 patients without EPO treatment. Two groups of premature infants after the first 10 days of oral iron and vitamin E, if necessary, blood transfusions. Results: After 8 weeks of treatment, the RBC, Hb and Ret of the treatment group were significantly higher than those of the control group (P <0.01). Conclusion: Early application of EPO can prevent anemia in premature infants and reduce the number of transfusions in preterm infants.